Kronos Bio
KRON

$0.9561

3.91%

Market Cap: $57.6M

About: Kronos Bio Inc is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel cancer therapeutics designed to transform patient outcomes through a precision medicine plan by targeting dysregulated transcription. The company operates in one business segment, the development of biopharmaceutical products.

Employees: 58

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 6,710 funds

–

Analysts bullish %

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

7% more repeat investments, than reductions

Existing positions increased: 16 | Existing positions reduced: 15

0% more funds holding in top 10

Funds holding in top 10: 1 [Q1] → 1 (+0) [Q2]

1.85% less ownership

Funds ownership: 36.17% [Q1] → 34.32% (-1.85%) [Q2]

5% less funds holding

Funds holding: 58 [Q1] → 55 (-3) [Q2]

10% less capital invested

Capital invested by funds: $28.3M [Q1] → $25.5M (-$2.76M) [Q2]

33% less first-time investments, than exits

New positions opened: 6 | Existing positions closed: 9

See Fund Rankings

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$2.25

135%

upside

Avg. target

$2.25

135%

upside

High target

$2.25

135%

upside

2 analyst ratings

2 positive

100%

0 neutral

0%

0 negative

0%

HC Wainwright & Co. Robert Burns 47% 1-year accuracy 62 / 132 met price target	135%upside $2.25	Buy Reiterated	19 Aug 2024
HC Wainwright & Co. Robert Burns 47% 1-year accuracy 62 / 132 met price target	135%upside $2.25	Buy Reiterated	1 Aug 2024

See Analyst Rankings

Financial journalist opinion

Based on 3 articles about KRON published over the past 30 days

Zacks Investment Research

After Plunging -5.53% in 4 Weeks, Here's Why the Trend Might Reverse for Kronos Bio (KRON)

The heavy selling pressure might have exhausted for Kronos Bio (KRON) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

After Plunging -5.53% in 4 Weeks, Here's Why the Trend Might Reverse for Kronos Bio (KRON)

Kronos Bio Announces Participation in Medical and Investor Conferences in September

SAN MATEO, Calif., and CAMBRIDGE, Mass., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to developing small molecule therapeutics that address cancers and other diseases driven by deregulated transcription, today announced the following upcoming conferences:

Kronos Bio Announces Participation in Medical and Investor Conferences in September

Zacks Investment Research

After Plunging -23.49% in 4 Weeks, Here's Why the Trend Might Reverse for Kronos Bio (KRON)

Kronos Bio (KRON) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

After Plunging -23.49% in 4 Weeks, Here's Why the Trend Might Reverse for Kronos Bio (KRON)

Zacks Investment Research

Kronos Bio, Inc. (KRON) Expected to Beat Earnings Estimates: Should You Buy?

Kronos Bio (KRON) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Kronos Bio, Inc. (KRON) Expected to Beat Earnings Estimates: Should You Buy?

Kronos Bio Announces First Patient Dosed with KB-0742 in an Expansion Cohort Focused on Platinum-Resistant High-Grade Serous Ovarian Cancer

— KB-0742 cleared 80mg four-days-on, three-days-off dosing schedule in dose escalation — — Company expects to provide an efficacy update on this expansion cohort in 1H 2025 — SAN MATEO, Calif. and CAMBRIDGE, Mass.

Kronos Bio Announces First Patient Dosed with KB-0742 in an Expansion Cohort Focused on Platinum-Resistant High-Grade Serous Ovarian Cancer

Kronos Bio to Present Clinical Update on Phase 1/2 Trial of KB-0742 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

— KB-0742 continues to demonstrate a manageable safety and tolerability profile with no grade 3/4 neutropenia observed —

Kronos Bio to Present Clinical Update on Phase 1/2 Trial of KB-0742 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Kronos Bio to Participate in Three Upcoming Healthcare Conferences and Events

SAN MATEO, Calif. and CAMBRIDGE, Mass., May 22, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to developing small molecule therapeutics that address cancers and other diseases driven by deregulated transcription, today announced that the company would participate in three upcoming healthcare conferences and events. Norbert Bischofberger, Ph.D., president and chief executive officer, will represent the company at these events.

Kronos Bio to Participate in Three Upcoming Healthcare Conferences and Events

Kronos Bio Appoints Deborah Knobelman, Ph.D. as Chief Operating Officer and Chief Financial Officer

SAN MATEO, Calif. and CAMBRIDGE, Mass., May 21, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to developing small molecule therapeutics that address cancers and other diseases driven by deregulated transcription, today announced that it has appointed Deborah Knobelman, Ph.D., as Chief Operating Officer and Chief Financial Officer effective June 3, 2024. Dr. Knobelman will oversee the finance, accounting, business development, investor relations and corporate strategy functions.

Kronos Bio Appoints Deborah Knobelman, Ph.D. as Chief Operating Officer and Chief Financial Officer

Zacks Investment Research

Down -5.63% in 4 Weeks, Here's Why Kronos Bio (KRON) Looks Ripe for a Turnaround

Kronos Bio (KRON) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Down -5.63% in 4 Weeks, Here's Why Kronos Bio (KRON) Looks Ripe for a Turnaround

Zacks Investment Research

Kronos Bio, Inc. (KRON) Reports Q1 Loss, Tops Revenue Estimates

Kronos Bio, Inc. (KRON) came out with a quarterly loss of $0.50 per share versus the Zacks Consensus Estimate of a loss of $0.43. This compares to loss of $0.46 per share a year ago.

Kronos Bio, Inc. (KRON) Reports Q1 Loss, Tops Revenue Estimates

See News Rankings